Skip to main content
SpringerLink
Log in

Antiphospholipid Antibody Syndrome

  • Chapter
  • First Online:
Hemocoagulative Problems in the Critically Ill Patient

  • 1303 Accesses

Abstract

Antiphospholipid antibody (APLA) syndrome (APS) is a heterogeneous disorder defined by the finding of persistent APLA in patients with arterial or venous thrombosis or pregnancy morbidity. APS manifestations range from deep vein thrombosis to stroke and even rapid multiorgan failure (the rare “catastrophic APS”). APS may be primary or secondary; in both cases, however, the clinical consequences appear to be the same. Although crucial to thrombotic risk assessment and clinical management, current laboratory testing for APLA lacks standardization and data from randomized trials. Consequently, correlating laboratory findings with clinical features is still a challenge for clinicians facing APS. This chapter presents the current definition of APS and discusses its etiopathogenesis and diagnosis and approaches for its treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wassermann A, Neisser A, Bruck C (1906) Eine serodiagnostische reaction bei Syphilis. Dtsch Med Wochenschr 32:745–746

    Article  Google Scholar 

  2. Matsuura E, Igasrashi Y, Fujimoto M et al (1992) Heterogeneity of anticardiolipin antobodies defined by anticardiolipin cofactor. J Immunol 144:3885–3891

    Google Scholar 

  3. Forestiero RR, Martinuzzo ME, Kordich LC, Carreras LO (1996) Reactivity to β2-glycoprotein I clearly differentiates anticardiolipin antibodies from anti-phospholipid syndrome and syphilis. Thromb Haemost 75:717–720

    Google Scholar 

  4. Triplett DA (2002) Antiphospholipid antibodies. Arch Pathol Lab Med 126:1424–1429

    PubMed  CAS  Google Scholar 

  5. Brandt JT, Triplett DA, Alving B, Scharrer I (1995) Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 74:1185–1190

    PubMed  CAS  Google Scholar 

  6. Tripodi A, Chantarangkul V, Clerici M et al (2002) Laboratory diagnosis of lupus anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. Thromb Haemost 88:583–586

    CAS  Google Scholar 

  7. Harris EN, Pierangeli SS (2002) Revisiting the anticardiolipin test and its standardization. Lupus 11:269–275

    Article  PubMed  CAS  Google Scholar 

  8. Harris EN (1990) Special report: the second international anti-cardiolipin standardization workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 94:476–484

    PubMed  CAS  Google Scholar 

  9. Long AA, Ginsberg JS, Brill-Edwards P et al (1991) The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost 66:520–524

    PubMed  CAS  Google Scholar 

  10. Galli M, Luciani D, Bertolini G, Barbui T (2003) Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 102:2717–2723

    Article  PubMed  CAS  Google Scholar 

  11. de Groot PG, Horbach DA, Simmelink MJ et al (1998) Anti-prothrombin antibodies and their ralation with thrombosis and lupus anticoagulant. Lupus 7(Suppl 2):S32–S36

    Article  PubMed  Google Scholar 

  12. Satoh A, Suzuki K, Takayama E et al (1999) Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 26:1715–1720

    PubMed  CAS  Google Scholar 

  13. de Groot PG, Derksen RH (2005) Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 3:1854–1860

    Article  PubMed  Google Scholar 

  14. Hemker HC, Dieri RA, De Smedt E, Béguin S (2006) Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 96:553–561

    PubMed  CAS  Google Scholar 

  15. Membre A, Wahl D, Latger-Cannard V et al (2008) The effect of platelet activation on the hypercoagulability induced by murine monoclonal antiphospholipid antibodies. Haematologica 93:566–573

    Article  PubMed  CAS  Google Scholar 

  16. Vila P, Hernandez MC, Lopez-Fernandez MF et al (1994) Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 72:209–213

    PubMed  CAS  Google Scholar 

  17. Ginsberg JS, Wells PS, Brill-Edwards P et al (1995) Antiphospholipid antibodies and venous thromboembolism. Blood 86:3685–3691

    PubMed  CAS  Google Scholar 

  18. Mateo J, Oliver A, Borrell M et al (1997) Laboratory evaluation and clinical characteristic of 2,132 consecutive unselected patients with venous thromboembolism: results of the Spanish multicentric study on thrombophilia (EMET-study). Thromb Haemost 77:444–451

    PubMed  CAS  Google Scholar 

  19. Galli M, Luciani D, Bertolini G et al (2003) Lupus anticoagulants are stronger risk factor for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101:1827–1832

    Article  PubMed  CAS  Google Scholar 

  20. Wilson WA, Gharavi AE, Koike T et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311

    Article  PubMed  CAS  Google Scholar 

  21. Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306

    Article  PubMed  CAS  Google Scholar 

  22. Tincani A, Allegri F, Sanmarco M et al (2001) Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations: a cooperative project of the European antiphospholipid forum. Thromb Haemost 86:575–583

    PubMed  CAS  Google Scholar 

  23. Brandt JT, Barna LK, Triplett DA (1995) Laboratory identification of lupus anticoagulants: results of the second international workshop for identification of lupus anticoagulants. Thromb Haemost 74:1597–1603

    PubMed  CAS  Google Scholar 

  24. Asherson RA (1992) The catastrophic antiphospholipid syndrome. J Rheumatol 19:508–512

    PubMed  CAS  Google Scholar 

  25. Bucciarelli S, Espinosa G, Cervera R et al (2006) For the CAPS registry project group (european forum on antiphospholipid antibodies): mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 54:2568–2576

    Article  PubMed  Google Scholar 

  26. Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027

    Article  PubMed  Google Scholar 

  27. Asherson RA, Cervera R, Piette JC et al (1998) Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine (Baltimore) 77:195–207

    Article  CAS  Google Scholar 

  28. Dentali F, Crowther M (2010) Antiphospholipid antibodies in critical illness. Crit Care Med 38(Suppl 2):S51–S56

    Article  PubMed  CAS  Google Scholar 

  29. Kitchens CS (1998) Thrombotic storm: when thrombosis begets thrombosis. Am J Med 104:381–385

    Article  PubMed  CAS  Google Scholar 

  30. Meroni PL (2008) Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of the autoimmunity. J Autoimmun 30:99–103

    Article  PubMed  CAS  Google Scholar 

  31. Espinosa G, Cervera R (2009) Morbidity and mortality in the antiphosholipid syndrome. Curr Opin Pulm Med 15:413–417

    Article  PubMed  CAS  Google Scholar 

  32. Hudson M, Herr AL, Rauch J et al (2003) The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol 30:2385–2391

    PubMed  CAS  Google Scholar 

  33. Schulman S, Svenungsson E, Granqvist S (1998) Duration of Anticoagulation Study Group: anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 104:332–338

    Article  PubMed  CAS  Google Scholar 

  34. Kearon C, Gent M, Hirsh J et al (1999) A comparison of three month of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340:901–907

    Article  PubMed  CAS  Google Scholar 

  35. Kearon C, Ginsberg JS, Kovacs MJ et al (2003) Comparison of low-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349:631–639

    Article  PubMed  CAS  Google Scholar 

  36. Rosove MH, Brewer PM (1992) Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 117:303–308

    PubMed  CAS  Google Scholar 

  37. Khamashta MA, Cuadrato MJ, Mujic F et al (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993–997

    Article  PubMed  CAS  Google Scholar 

  38. Finazzi G, Brancaccio V, Moia M et al (1996) Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four years prospective study from the Italian Registry. Am J Med 100:530–536

    Article  PubMed  CAS  Google Scholar 

  39. Tsapanos V, Kanellopoulos N, Cardamakis E et al (2000) Anticardiolipin antibodies level in healthy pregnant and non-pregnant women. Arch Gynecol Obstet 263:111–115

    Article  PubMed  CAS  Google Scholar 

  40. Oshiro BT, Silver RM, Scott JR et al (1996) Antiphospholipid antibodies and fetal death. Obstet Gynecol 87:489–493

    Article  PubMed  CAS  Google Scholar 

  41. Rai RS, Clifford K, Cohen H et al (1995) High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 10:3301–3304

    PubMed  CAS  Google Scholar 

  42. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR (1992) Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 80:614–620

    PubMed  CAS  Google Scholar 

  43. Out HJ, Bruinse HW, Christiens GC et al (1992) A prospective, controlled, multicenter study on the obstetric risk in pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol 167:26–32

    PubMed  CAS  Google Scholar 

  44. Buller HR, Agnelli G, Hull RD et al (2004) Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolitic therapy. Chest 126:401S–428S

    Article  PubMed  CAS  Google Scholar 

  45. Garcia DA, Khamashta MA, Crowther MA (2007) How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. Blood 110:3122–3127

    Article  PubMed  CAS  Google Scholar 

  46. Crowther MA, Ginsberg JS, Julian J et al (2003) A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349:1133–1138

    Article  PubMed  CAS  Google Scholar 

  47. Finazzi G, Marchioli R, Brancaccio V et al (2005) A randomized clinical trial of high-intensity warfarin vs conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3:848–853

    Article  PubMed  CAS  Google Scholar 

  48. Tenedios F, Erkan D, Lockshin MD (2005) Cardiac involvement in the antiphospholipid syndrome. Lupus 14:691–696

    Article  PubMed  CAS  Google Scholar 

  49. The APASS Writing Committee (2004) Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004 291:576–584

    Google Scholar 

  50. Mohr JP, Thompson JL, Lazar RM et al (2001) A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345:1444–1451

    Article  PubMed  CAS  Google Scholar 

  51. Brey RL, Chapman J, Levin SR et al (2003) Stroke and antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus 12:508–513

    Article  PubMed  CAS  Google Scholar 

  52. Okuma H, Kitagawa Y, Yasuda T et al (2009) Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci 7:15–18

    PubMed  Google Scholar 

  53. Alagorn-Segovia D, Boffa MC, Branch W et al (2003) Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 12:499–503

    Article  Google Scholar 

  54. Erkan D, Harrison MJ, Levi R et al (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-bind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 56:2382–2391

    Article  PubMed  CAS  Google Scholar 

  55. Vivaldi P, Rossetti G, Galli M, Finazzi G (1997) Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature. Haematologica 82:345–347

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Anesthesia and Intensive Care, Cattinara Hospital, University of Trieste, Strada di Fiume 447, Trieste, Italy

    Marco Zambon, Davide Cappelli & Giorgio Berlot

Authors
  1. Marco Zambon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Davide Cappelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giorgio Berlot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marco Zambon .

Editor information

Editors and Affiliations

  1. , Department of Anesthesia and Intensive C, University of Trieste, Strada di Fiume 447, Trieste, I-34149, Italy

    Giorgio Berlot

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Italia

About this chapter

Cite this chapter

Zambon, M., Cappelli, D., Berlot, G. (2012). Antiphospholipid Antibody Syndrome. In: Berlot, G. (eds) Hemocoagulative Problems in the Critically Ill Patient. Springer, Milano. https://doi.org/10.1007/978-88-470-2448-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-2448-9_13

  • Published:

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-2447-2

  • Online ISBN: 978-88-470-2448-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation